Participated · Seed · Apr 2024

AmaliaCare operates an AI-driven platform that helps families find and manage professional caregivers by profiling the care recipient, identifying required caregiver characteristics, and using algorithms and adaptive questions to surface best matches. The company was founded in October 2020 in Brescia by Sonia Paonessa and Eliana Pérez. To date it has served 650 families across 19 Italian regions and received over 60,000 caregiver applications. AmaliaCare has closed an equity capital increase (seed) of over €1 million. The new funds will be used to develop the algorithm and platform, expand the team, scale marketing, and open two new offices in Milan and Turin. The team aims to reach six physical offices across Lombardy, Piedmont, Emilia-Romagna, Tuscany and Veneto by 2025 and to support over 5,000 families in Italy within five years.

Led · Equity · Mar 2024

Id.Eight is a startup that produces sustainable, cruelty‑free, genderless sneakers using low‑impact materials sourced from food‑industry waste. Founded in 2019, the company uses bio‑based leathers such as Uppeal and Vegea (from apple peels and grape pomace), Pinatex (pineapple leaves) and BioVeg (from corn), plus recycled polyester and organic cotton for uppers, linings and insoles. Packaging is made from recycled paper and includes a seed "bomb" to support biodiversity and pollinators. The brand emphasizes continuous models to fight overproduction and cites the broader sustainable footwear market at $9.17 billion, with a projected rise to $14 billion by 2031. Id.Eight has grown its presence in Italy and abroad and plans to scale production, expand its product range, and pursue further internationalization, particularly in Germany and the Netherlands. The founders say they will invest in R&D to test new materials and eco‑design solutions while maintaining high standards of quality and sustainability.

Participated · Equity · Feb 2023

Harg, founded in 2017 in Cremona, develops, produces and commercializes dehydrated, texture‑modified food preparations for people with dysphagia under the Dysphameal brand. Its products were developed with the University of Genoa, are nutrient‑enriched and targeted at frail elderly patients across Italy and Europe. The company is organized as a Società Benefit and has created HARG Academy to inform and educate customers and key opinion leaders on dysphagia. Harg completed a €2.5 million capital increase in which €1 million was subscribed by the Fondo Rilancio Startup managed by CDP Venture Capital SGR and €1.5 million by Gruppo Brixia, a|impact, Etica Sgr and Mazza Srl, bringing approved share capital to €7.475 million. Management says the funding will support growth projects, strengthen its presence in Italy and pursue commercial and informational initiatives. The company aims to reach 10 million annual distributions by the end of 2023.

Participated · Seed · Feb 2022

Founded in 2017 and based in Rome, GenomeUp develops an AI-powered medical SaaS platform for genomic analysis and clinical decision support focused on rare genetic diseases. Its flagship product, JuliaOmix, enables physicians and genetic biologists to collaborate by combining patients' symptoms, treatments, phenotypes and omics data (whole genome, exome, microbiome). The platform produces AI-based clinical interpretation and reports of genomic variants to aid diagnosis and treatment planning. GenomeUp says its longer-term goal is to build a reference platform to accelerate diagnosis times, improve patient care, and deepen understanding of genetic diseases. The company has developed bioinformatics tools and protocols to make health data traceable, accessible, interoperable and reusable for researchers and clinicians. Its recent fundraising will be used to grow the team and continue platform development. GenomeUp is a Rome-based university spin-off that develops a genomic tool leveraging artificial intelligence to help doctors choose the best treatments for patients. The product analyzes a patient’s genome to generate detailed clinical reports on genes affecting pathology, the severity of new mutations, and personalized treatments by mining PubMed. The company plans to use recent funding to continue development efforts. GenomeUp recently completed the LUISS EnLabs accelerator run by LVenture Group. It has partnered with Ospedale Pediatrico Bambino Gesù and Policlinico Tor Vergata in Rome. Leadership includes CEO Simone Gardini, CTO Andrea Spinelli, and COO Andrea Cocco.